Congenital prekallikrein deficiency is a rare, inherited blood-clotting factor deficiency. Many people with congenital prekallikrein deficiency have no symptoms, and bleeding is usually mild if it occurs. It is lifelong and often first noticed during routine blood tests that show a long aPTT. People of any age can be diagnosed, and family members may share the trait. Treatment is usually not needed, but doctors may use standard clotting support for procedures or injuries, and life expectancy is typically normal.
Overview
Congenital prekallikrein deficiencySymptoms
Most people with congenital prekallikrein deficiency have no noticeable signs. It’s often found when a routine blood test shows a prolonged clotting time (aPTT), without abnormal bleeding. Rarely, doctors watch for other causes of bruising or uncommon clots.
Outlook and prognosis
Many people with congenital prekallikrein deficiency never develop symptoms and have a typical life expectancy. When symptoms occur, they’re usually mild—such as easy bruising or nosebleeds—and respond to standard bleeding care. Surgery and pregnancy generally go smoothly with planning.
Causes and risk factors
Congenital prekallikrein deficiency results from inherited changes in the KLKB1 gene, passed in an autosomal recessive pattern. Risk rises when both parents are carriers, with higher carrier rates reported in some African and African American populations. Consanguinity increases likelihood.
Genetic influences
Genetics play a central role in congenital prekallikrein deficiency. It’s usually inherited in an autosomal recessive pattern, meaning two altered KLKB1 gene copies are needed. Variants influence prekallikrein levels, lab results (like prolonged aPTT), and rarely, bleeding or clotting tendencies.
Diagnosis
Doctors suspect it with an isolated prolonged aPTT on routine clotting tests that corrects on mixing or shortens after incubation. Specific assays show markedly reduced prekallikrein activity. Genetic diagnosis of congenital prekallikrein deficiency uses KLKB1 testing to confirm.
Treatment and drugs
Treatment for congenital prekallikrein deficiency focuses on preventing and managing bleeding or swelling episodes if they occur. Care may include antifibrinolytics for procedures, factor replacement if another clotting problem is present, and careful planning before surgery or dental work. Regular follow-up with a hematology team helps tailor care.
Symptoms
Many people with congenital prekallikrein deficiency don’t notice any day-to-day problems. It’s often picked up when a routine pre-surgery blood test shows a very long clotting time, even though bleeding in daily life is normal. Features vary from person to person and can change over time. Early features of congenital prekallikrein deficiency are often absent, so information usually comes from the lab report rather than from how someone feels.
Most people do not bleed more than usual in daily life. Cuts and dental work usually behave as expected.
A routine test may show a very long clotting time (aPTT), often before a procedure. This is common in congenital prekallikrein deficiency and can look serious even when you feel well.
Rarely, extra bleeding follows major surgery, deep wounds, or dental extractions. Share your history so your team can plan and monitor.
A few reports link congenital prekallikrein deficiency to blood clots in the legs or lungs. Most people never develop clots, and overall risk appears low.
How people usually first notice Congenital prekallikrein deficiency?
Many people learn about congenital prekallikrein deficiency only after routine blood tests show an unusually long aPTT (a lab measure of clotting time) even though they’ve never had unusual bleeding. Doctors often first suspect it when the aPTT stays prolonged despite mixing tests that correct for other causes, or when a family member has similar lab results without bleeding symptoms. In newborns or children, the first signs of congenital prekallikrein deficiency are typically not outward symptoms but these unexpected lab findings during evaluations for surgery, bruising checks, or unrelated illnesses—this is how the first signs of congenital prekallikrein deficiency are most often noticed.
Types of Congenital prekallikrein deficiency
Congenital prekallikrein deficiency is a rare inherited clotting-factor disorder that mainly shows up on lab tests rather than in day-to-day bleeding problems. Most people feel well and do not have unusual bruising or bleeding, even if a screening test called the aPTT is prolonged. Symptoms don’t always look the same for everyone. Clinicians often describe them in these categories: complete (no measurable activity) versus partial (reduced activity), with a few named lab-pattern variants; these variants help explain differences in test results more than differences in how people feel.
Type I deficiency
Activity is extremely low or undetectable on testing. People usually have no bleeding problems in daily life. Some may have nosebleeds or easy bruising during illness or surgery, but this is uncommon.
Type II deficiency
Activity is low but not absent on testing. Most people live without bleeding symptoms and discover the condition during routine blood work. Lab results often show a prolonged aPTT that corrects with mixing studies.
Fletcher trait
This variant shows very low prekallikrein activity with a characteristically prolonged aPTT that shortens after the sample sits in the lab. People feel well and typically have no extra bleeding with dental work or minor procedures.
Williams trait
This variant shows reduced prekallikrein activity with a similar lab pattern of aPTT correction after incubation. Day-to-day life is unaffected for most, and bleeding risk remains low. Doctors may repeat tests to confirm the pattern.
Heterozygous carriers
One working and one altered gene lead to mildly reduced levels. Carriers often have normal lives and may have a borderline or mildly prolonged aPTT. Not everyone will experience every type.
Laboratory-only variant
Some have unusual test patterns without clear symptoms, highlighting types of congenital prekallikrein deficiency that matter more to labs than to daily health. Family screening can reveal similar results in relatives. If you notice one or more of these symptom types, bring it up at your next appointment.
What genetics can tell you about symptoms
Some people with congenital prekallikrein deficiency have no symptoms, while certain genetic variants can delay clot formation and lead to easy bruising, nosebleeds, or heavy periods. Rare changes may also trigger swelling episodes (angioedema‑like) without hives, linked to altered kallikrein–kinin signaling.
Causes and risk factors
Congenital prekallikrein deficiency is caused by changes in the KLKB1 gene that lower prekallikrein levels. It happens when both parents carry the same change, so a child receives two copies. Having risk factors doesn’t mean you’ll definitely develop the condition. Risk factors for congenital prekallikrein deficiency include family history, parents who are related by blood, and communities with more carriers. Illness, surgery, pregnancy, or blood thinners do not cause it, but they can change clotting tests or make congenital prekallikrein deficiency more noticeable.
Environmental and biological risk factors
Congenital prekallikrein deficiency is present from birth, and most people have no symptoms early on. Because early symptoms of congenital prekallikrein deficiency are uncommon, risk assessments focus on background biological and environmental factors. Doctors often group risks into internal (biological) and external (environmental). So far, no specific external exposures or common pregnancy-related factors have been proven to raise the chance of it occurring.
No specific environmental toxins have been linked to causing congenital prekallikrein deficiency. Available reports have not shown associations with air pollution, heavy metals like lead or mercury, or endocrine-disrupting chemicals.
Diagnostic or occupational radiation exposure has not been associated with higher risk of this condition. Standard medical imaging doses in pregnancy have not been shown to cause it.
Common infections during pregnancy, such as influenza or COVID-19, have not been shown to cause this deficiency. No specific prenatal infection has been tied to increased risk.
Advanced maternal or paternal age does not appear to raise the likelihood of congenital prekallikrein deficiency. Unlike chromosome-related conditions, risk does not track with parent age.
Genetic risk factors
In congenital prekallikrein deficiency, most cases arise when both copies of the KLKB1 gene carry changes that lower or stop prekallikrein production. Risk is not destiny—it varies widely between individuals. Early symptoms of congenital prekallikrein deficiency are often absent, so the genetic change may first be noticed when a routine clotting test (aPTT) is longer than expected. People who carry a single changed copy (carriers) usually have normal health.
KLKB1 gene variants: Changes in the KLKB1 gene reduce or stop production of plasma prekallikrein. When both gene copies are affected, congenital prekallikrein deficiency develops. Many variants are unique to individual families.
Autosomal recessive pattern: You typically need one changed gene from each parent to be affected. Carriers with one changed copy usually have normal health and no bleeding problems.
Biallelic changes: Having two disease-causing KLKB1 variants (homozygous or compound heterozygous) leads to very low prekallikrein levels and a prolonged clotting test. Some people have no symptoms despite these lab findings.
Family history risk: If both parents are carriers, each pregnancy has a 25% chance of a child with congenital prekallikrein deficiency. Brothers and sisters may be affected or be carriers even if no one notices problems.
Parental relatedness: When parents are related by blood, they are more likely to share the same KLKB1 variant. This raises the chance their child inherits two altered copies.
Variant type matters: Gene changes that completely disrupt KLKB1 often leave almost no protein, while some single-letter changes preserve partial function. The specific variant can influence how low the prekallikrein level is and how abnormal the clotting test appears.
Lifestyle risk factors
Lifestyle habits do not cause Congenital prekallikrein deficiency, but they can influence how the condition is experienced and whether complications, especially blood clots, are more likely. Evidence suggests most people do not bleed more, yet some reports link the disorder to thrombosis, so general clot‑risk habits matter. Below are practical ways how lifestyle affects Congenital prekallikrein deficiency, focusing on circulation, vascular health, and procedure safety. These considerations align with lifestyle risk factors for Congenital prekallikrein deficiency without implying the condition is lifestyle‑driven.
Long periods of sitting or low activity can promote venous stasis and increase baseline clot risk, which is relevant if your contact pathway disorder leans prothrombotic. Regular movement, walking, and leg exercises support circulation and may reduce venous thromboembolism risk.
Long-haul travel or bedrest slows venous return and can raise the chance of leg clots in susceptible people. Planning frequent walk-and-stretch breaks and calf pumps during travel helps maintain blood flow.
Low fluid intake can thicken blood (hemoconcentration) and may nudge the body toward clotting. Steady hydration supports smoother circulation, especially during illness, heat, or travel.
Nicotine and smoke constituents damage endothelium and tilt the balance toward thrombosis. Quitting reduces vascular inflammation and may lower clot-related complications in this condition.
Risk prevention
Congenital prekallikrein deficiency is inherited, so you can’t prevent the condition itself, but you can lower the chance of complications. Many people have no symptoms, and early symptoms of congenital prekallikrein deficiency are often absent. The main goal is to avoid misdiagnosis, ensure safe surgery or dental work, and use the right tests if blood thinners are needed. Talk to your doctor about which preventive steps are right for you.
A genetics visit can explain inheritance and chances for children. It can also discuss carrier testing for family members.
Carry a medical ID card noting congenital prekallikrein deficiency and prolonged aPTT. Keep copies of key lab results to show during emergencies or new visits.
Tell surgical and dental teams ahead of time that aPTT runs long with this condition. This helps avoid delays, unnecessary transfusions, or incorrect bleeding precautions.
If you ever need heparin, ask your team to monitor with anti-Xa levels, not aPTT, because aPTT is naturally prolonged in this condition. This helps prevent under- or over-dosing.
Transmission
Congenital prekallikrein deficiency is a genetic condition, not an infection, so it cannot be caught or spread to others. Most people with congenital prekallikrein deficiency inherit it in an autosomal recessive way, meaning a child needs two nonworking copies of the gene—one from each parent, who are usually healthy carriers. When both parents are carriers, each pregnancy has a 25% (1 in 4) chance of a child with the condition, a 50% (1 in 2) chance of a carrier child, and a 25% (1 in 4) chance of a child with neither copy. Rare new gene changes can arise, but how congenital prekallikrein deficiency is inherited in most families is through two carrier parents rather than anything contagious.
When to test your genes
Consider genetic testing if you have lifelong, unexplained prolonged aPTT on blood tests with normal bleeding history, or if close relatives have confirmed prekallikrein deficiency. Testing can clarify diagnosis, prevent unnecessary procedures, and guide lab teams to use appropriate assays. Seek it before surgery or if planning a family.
Diagnosis
Congenital prekallikrein deficiency is often found by accident, such as during routine pre-surgery blood work, because most people have no bleeding symptoms. Doctors usually begin by reviewing your health history and ordering a few clotting tests to see why one test looks unusually prolonged. Many people feel relief just knowing what’s really going on. The diagnosis of congenital prekallikrein deficiency is confirmed with specialized blood tests and may be supported by genetic testing.
Your provider asks about easy bruising, nosebleeds, or past surgery and dental work, plus any family history of unusual blood test results. Most people with this condition report no bleeding problems.
A common clotting test called the aPTT often appears prolonged, while other basic tests are normal. This pattern can be the first clue that points toward a contact-factor deficiency rather than a true bleeding risk.
Your plasma is mixed with normal plasma to see if the prolonged aPTT corrects. Full correction suggests a missing protein (deficiency), not an inhibitor like an antibody or medication effect.
Letting the sample sit warm for a while can shorten the aPTT in prekallikrein deficiency. This time-dependent correction is a classic lab feature that helps distinguish it from other causes.
Stages of Congenital prekallikrein deficiency
Congenital prekallikrein deficiency does not have defined progression stages. It’s an inherited, lifelong but stable blood-clotting factor shortage that usually causes no symptoms and is typically picked up by lab testing rather than gradual changes over time. Doctors usually start with a conversation about your medical and family history and order clotting blood tests; a screening test called the aPTT is often prolonged, and follow-up assays are the tests used to diagnose congenital prekallikrein deficiency. Results also help rule out other causes of a prolonged aPTT and guide planning before procedures or surgery.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, and the short answer is that most people with congenital prekallikrein deficiency live normal lifespans and feel well day to day. Many living with this condition have no symptoms at all; others may notice easy bruising, nosebleeds, or prolonged bleeding after a dental procedure, but serious bleeding is uncommon. If you’ve just been diagnosed after an abnormal clotting test, you’re not alone—this condition often shows up on lab work before any issues are noticed. Doctors call this the prognosis—a medical word for likely outcomes.
The outlook is not the same for everyone, but the majority of people with congenital prekallikrein deficiency do not have increased mortality from the condition itself. There’s no strong evidence that it raises the risk of dangerous clots or life-threatening bleeds, though rare reports exist on both sides. Early symptoms of congenital prekallikrein deficiency can be so mild that they’re missed until surgery is planned or a tooth is pulled; planning ahead helps prevent surprises. With ongoing care, many people maintain full activity, have children safely, and undergo procedures with simple precautions.
Knowing what to expect can ease some of the worry. Before surgeries or new medications, your care team may coordinate a bleeding plan and flag drugs that interfere with clotting. Genetic testing can sometimes provide more insight into prognosis, especially when family members have different experiences, but not everyone with the same gene change will have the same outlook. Talk with your doctor about what your personal outlook might look like, including any other health factors that could influence bleeding or clotting risk.
Long-term effects
For most people with congenital prekallikrein deficiency, day-to-day life feels normal, and the condition is often found by chance during blood tests. Long-term effects vary widely, but many have no bleeding issues despite an abnormal lab result. The main impact over the years is usually related to test results rather than how someone feels. A small number of reports suggest a possible link with blood clots, though overall risk appears low.
People rarely notice early symptoms of congenital prekallikrein deficiency. Most live without bleeding problems. Features tend to stay stable over time.
The blood test called aPTT remains markedly prolonged lifelong. This laboratory feature often doesn’t match how people feel day to day.
Everyday cuts and dental work typically do not cause unusual bleeding. Outcomes with major procedures are generally similar to those without the condition.
Some reports link congenital prekallikrein deficiency to venous or arterial clots. Evidence is limited, and the overall likelihood appears low.
How is it to live with Congenital prekallikrein deficiency?
Daily life with congenital prekallikrein deficiency is often uneventful because most people have no symptoms and discover it only after a routine blood test shows a prolonged aPTT (a lab clotting time) without a history of abnormal bleeding. When it does matter is around surgeries, dental work, or new medications—sharing the diagnosis with your care team helps them interpret labs correctly and avoid unnecessary delays or invasive tests. Family members may feel concerned when they hear “abnormal clotting test,” but reassurance comes from the key point: this condition typically does not cause bleeding problems, and most live fully without activity restrictions. Regular communication with clinicians and keeping a summary of your diagnosis handy can make appointments smoother and ease worries for you and those close to you.
Treatment and drugs
Treatment for congenital prekallikrein deficiency focuses on what you feel day to day, because most people have no symptoms and do not need regular therapy. If you do have bleeding after surgery, dental work, or an injury, doctors typically manage it the same way they would for anyone with bleeding, using local measures like pressure and stitches, antifibrinolytic medicines (such as tranexamic acid), or blood products if needed. Preventive treatment before planned procedures may be advised based on your personal and family history rather than lab test results alone, since this condition can make clotting tests look delayed even when bleeding risk is low. Doctors sometimes recommend a combination of lifestyle changes and drugs to prepare for specific situations, for example planning dental care with antifibrinolytics on hand and avoiding unnecessary blood thinners unless there’s a clear reason. Ask your doctor about the best starting point for you, especially if you’ve had troublesome bleeding or have surgery coming up.
Non-drug treatment
People with congenital prekallikrein deficiency usually feel well in daily life, but the prolonged lab test (aPTT) can complicate check-ins before surgery or dental work. Many have no early symptoms of congenital prekallikrein deficiency, so planning ahead matters most. Non-drug treatments often lay the foundation for smooth care, helping you avoid unnecessary procedures while staying safe. The aim is to share your diagnosis clearly, prepare for procedures, and use simple, practical steps to manage bruises or recovery after injuries.
Carry a medical alert card or bracelet that states congenital prekallikrein deficiency and prolonged aPTT. This helps emergency and surgical teams avoid delays or unneeded treatments.
Let your primary clinician, hematology team, surgeon, dentist, and anesthesiologist know your diagnosis in advance. A brief plan on file prevents confusion when the aPTT shows as prolonged.
For surgery or dental work, teams can rely on local measures—firm pressure, careful stitching, and hemostatic dressings—and monitor closely. Most people do not need blood products solely because the aPTT is prolonged.
In hospital or after surgery, early walking and devices that squeeze the calves can reduce clot risk. These methods help when you cannot move much.
Your genes may have an impact on how drugs work for you
Genes can affect how your body processes medications used for congenital prekallikrein deficiency, changing how strongly a drug works or how long it lasts. Pharmacogenetic differences may guide dose choices, monitoring plans, or selection between options like replacement products and anticoagulation strategies.
Pharmacological treatments
Most people with congenital prekallikrein deficiency don’t need daily medicine. When medication is used, it’s usually for a short-term need such as getting ready for surgery or treating a blood clot. In practice, medications for congenital prekallikrein deficiency focus on temporarily replacing the missing protein with plasma, or using standard blood thinners if a clot occurs. Doctors adjust treatment plans regularly to match your situation and lab results.
Used before surgery or during active bleeding to temporarily raise prekallikrein and shorten an overly long aPTT. The effect is short-lived, so repeat doses may be needed based on lab checks.
Given in the hospital for clots such as deep vein thrombosis or pulmonary embolism. Because aPTT is already prolonged in congenital prekallikrein deficiency, dosing is guided by anti‑Xa levels rather than aPTT.
Enoxaparin or dalteparin can be used to prevent or treat clots at home or in hospital. Doses are based on body weight, with anti‑Xa monitoring in special situations like pregnancy, kidney disease, or extremes of weight.
Apixaban, rivaroxaban, dabigatran, or edoxaban treat and prevent many types of blood clots. They do not rely on aPTT for dosing, which can simplify care in congenital prekallikrein deficiency.
Genetic influences
Families often ask, “Is congenital prekallikrein deficiency inherited?” Yes—most cases are passed down in an autosomal recessive pattern. This means a child needs to inherit two nonworking copies of the KLKB1 gene, which helps the body make prekallikrein, to have the condition. Parents who each carry one changed copy typically have no symptoms. A “carrier” means you hold the gene change but may not show symptoms. If both partners are carriers, each pregnancy has about a 25% chance of a child with congenital prekallikrein deficiency, a 50% chance the child will be a carrier, and a 25% chance of neither. People who share the same KLKB1 change may still have different lab results, and most do not have extra bleeding problems. Genetic testing can identify changes in KLKB1 when routine clotting tests point to this diagnosis.
Is Congenital prekallikrein deficiency genetic?
Genetics play a central role in congenital prekallikrein deficiency. It’s usually inherited in an autosomal recessive pattern, meaning two altered KLKB1 gene copies are needed. Variants influence prekallikrein levels, lab results (like prolonged aPTT), and rarely, bleeding or clotting tendencies.
Pharmacogenetics—how genetics influence drug effects
Because congenital prekallikrein deficiency is caused by changes in the KLKB1 gene, the main treatment implications come from how it affects clotting tests rather than from bleeding itself. Not every difference in response is genetic, but recognizing this inherited deficiency early helps doctors avoid unnecessary plasma infusions and plan procedures safely. In congenital prekallikrein deficiency, the aPTT, a common clotting time test, is already prolonged, so people who need unfractionated heparin usually can’t be monitored with that test; anti‑Xa levels or other tests are preferred. If a blood thinner that relies on aPTT is used, such as argatroban or bivalirudin, teams may switch to drug‑specific tests or choose medicines that don’t require aPTT monitoring. There’s no evidence that KLKB1 changes alter how the body breaks down medicines, so standard dosing for most drugs—including antiplatelets and direct oral anticoagulants—is typically appropriate. A confirmed genetic diagnosis also reassures that routine factor replacement isn’t needed and helps everyone focus on managing other health risks that truly affect bleeding or clotting.
Interactions with other conditions
Because it can cause a very prolonged aPTT on blood tests without typical bleeding, congenital prekallikrein deficiency can complicate care when other conditions are present. Doctors call it a “comorbidity” when two conditions occur together, and the lab changes from congenital prekallikrein deficiency may hide or mimic other issues like lupus anticoagulant or factor XI deficiency, making diagnosis and surgical planning trickier. If someone also has a true bleeding disorder (for example, von Willebrand disease), bleeding risk usually reflects that other condition rather than the prekallikrein deficiency itself. On the flip side, this deficiency does not reliably protect against blood clots; if you have other clotting risks—such as immobilization, cancer, or inherited thrombophilia—standard clot prevention and treatment still apply. A practical interaction shows up with heparin treatment: because the aPTT is already prolonged, clinicians often monitor heparin with anti–factor Xa levels instead of aPTT to avoid dosing errors. Overall, coordinated care helps ensure that the abnormal aPTT is interpreted correctly alongside any other illnesses or medications.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described families where bruising seemed to appear easily and lab tests for clotting ran unusually long, yet major bleeding was rare. Before modern testing, many simply adjusted daily life—taking extra care with dental work or surgery—without a clear name for what was happening. As hospital laboratories expanded routine clotting panels in the mid‑20th century, a distinctive pattern emerged: a very prolonged aPTT test that corrected when mixed with normal plasma but didn’t match the usual causes.
From these first observations, specialists traced the issue to a missing or greatly reduced blood protein called prekallikrein, part of the “contact” side of the clotting system. Early case reports grouped it with other contact factor deficiencies and noted something puzzling: the lab abnormality looked dramatic, yet people with congenital prekallikrein deficiency typically did not have the heavy, spontaneous bleeding seen in classic hemophilia. This mismatch led to careful follow-up in families across several countries, confirming that the clotting test signal was strong while day‑to‑day bleeding risk was often low.
In recent decades, knowledge has built on a long tradition of observation. Researchers mapped the deficiency to changes in the KLKB1 gene, helping explain why it tends to run in families and why some communities reported more cases than others. As genetic testing became more available, reports shifted from single families to broader population snapshots, showing that many people discover congenital prekallikrein deficiency only when a pre‑surgery screen finds a prolonged aPTT.
Over time, descriptions became more precise. Doctors learned to separate prekallikrein deficiency from deficiencies of related factors like factor XII and high‑molecular‑weight kininogen, which can look similar on lab tests. They also recorded a wide range of lab results, from very low to moderately reduced levels, and noted that features vary: some people report easy bruising or nosebleeds, while many have no symptoms at all.
Looking back helps explain why the condition was once confusing. Early reports sometimes linked the abnormal test to bleeding risk, but larger studies clarified that most people with congenital prekallikrein deficiency do not bleed excessively in everyday life. Today, its history shapes practice: when an aPTT is prolonged without a clear cause, clinicians consider contact factor deficiencies and confirm the specific protein involved. This steady path—from puzzling lab clue to genetic understanding—means more accurate diagnosis, more measured counseling before procedures, and fewer delays caused by a test result that, for many, signals a benign variation rather than a dangerous bleeding disorder.